Diamyd Medical plans first interim report from the study DIAGNODE-1 where the diabetes vaccine Diamyd® is administered directly into lymph nodes
Diamyd Medical (Nasdaq Stockholm First North, Ticker: DMYD B) today announced in its first quarterly report for the fiscal year 2015/2016 that a first six month interim report for DIAGNODE-1, a clinical pilot study where the diabetes vaccine Diamyd® is administered directly into the lymph node, is intended to be presented during the first quarter of 2016. The study is open labeled, meaning not placebo-controlled. Professor Johnny Ludvigsson, Linköping University, is principal investigator and sponsor of the study. The report also announced that pre-clinical testing is ongoing to produce